Funded Startups in Emeryville
Emeryville’s largest disclosed round is Amyris at $400M on 2021-11-08, which dwarfs the rest of the disclosed amounts in this slice (the next-highest discl…
Emeryville’s largest disclosed round is Amyris at $400M on 2021-11-08, which dwarfs the rest of the disclosed amounts in this slice (the next-highest disclosed figures visible are $300M for Zymergen on 2020-09-08 and $200M for 4D Molecular Therapeutics on 2026-06-29). Sector activity also clusters: Biotechnology appears most frequently (10 of 37 rows), with additional concentrations in AI (3 rows) and Artificial Intelligence-adjacent “Data and Analytics” (3 rows). Temporally, the newest disclosed financing in view is 4D Molecular Therapeutics ($200M) on 2026-06-29, while the oldest dated rows span back to 2020-03-17 (Eureka Therapeutics), indicating coverage across multiple funding cycles.
Stage/amount reporting shows two notable classification gaps: “Series Unknown” appears in 10 of 37 rows, and “undisclosed” amounts appear in 4 of 37 rows (e.g., GatherOS.ai on 2025-12-11 and Geltor on 2025-08-07). Several entries also recur across time under the same company name (Sound Agriculture has rows in 2024-12-17 and 2020-05-19), which can affect how “recent” looks when comparing by amount alone.
Most recent rounds
37 shownRelated listings
Frequently asked
What’s the largest disclosed round in Emeryville here, and how extreme is it versus the rest?
Amyris’ $400M debt-related round on 2021-11-08 is the clear outlier: it sits well above the next-largest disclosed amounts visible ($300M for Zymergen on 2020-09-08 and $200M for 4D Molecular Therapeutics on 2026-06-29).
Are certain sectors over-represented among the 37 most recent dated entries?
Biotechnology is the dominant sector with 10 of 37 rows (e.g., 4D Molecular Therapeutics on 2026-06-29 at $200M, Ansa Biotechnologies on 2025-10-01 at $45M, and Nutcracker Therapeutics on 2022-03-14 at $167M). Artificial Intelligence appears 3 times (e.g., Metagenomi on 2023-01-05 at $100M; Eko Health on 2024-06-05 at $41M), and Agriculture and Farming appears 3 times (Sound Agriculture on 2024-12-17 at $25M and 2020-05-19 at $22M; Pattern Ag on 2022-08-25 at $35M).
How much of the list is missing stage or deal size disclosure, and where do those gaps show up?
Stage labeling is frequently incomplete: “Series Unknown” appears 10 of 37 rows (e.g., Longshot Space Technologies on 2026-06-23 at $5M; Oxide Computer Company on 2026-01-07 at $184M). Deal size can also be missing in 4 of 37 rows marked “undisclosed,” such as GatherOS.ai on 2025-12-11 and Geltor on 2025-08-07.
Which part of the timeline dominates, based on recency and repeated company activity?
The dataset spans 2020-03-17 (Eureka Therapeutics) through 2026-06-29 (4D Molecular Therapeutics), but it’s also skewed toward later rounds because all entries shown are the 37 most recent by date. Company recurrence is visible: Sound Agriculture appears at $25M on 2024-12-17 and at $22M on 2020-05-19, which can make the same name look both “recent” and “historically funded.”
Are there concentration patterns around a narrow date window that stand out?
There’s a noticeable mid-2025 cluster where multiple disclosed rounds land close together: Longshot Space Technologies on 2026-06-23 at $5M aside, the tightest visible run is 2025-07-22 to 2025-12-11, including Questflow ($7M) on 2025-07-22, Bolt ($4M) on 2025-08-14, and GatherOS.ai marked “undisclosed” on 2025-12-11.
Which entries look most like outliers on amount, excluding undisclosed rows?
Besides Amyris at $400M (2021-11-08), the high-end set also includes Zymergen at $300M (2020-09-08), Nutcracker Therapeutics at $167M (2022-03-14), Oxide Computer Company at $184M (2026-01-07), and Lucira Health at $80M (2022-02-04). At the low end of disclosed amounts, Injectsense at $3M (2023-11-15) and Bolt at $4M (2025-08-14) sit near the bottom relative to the bulk of rounds in the ~$10M–$50M range (e.g., Aralez Bio $12M on 2024-10-29 and Sound Agriculture $25M on 2024-12-17).
Know which startups just got funded. Every week.
Fresh funding rounds, new companies, and the sectors moving fastest — in your inbox every Monday morning.
Free. Sent every Monday. Unsubscribe anytime.